Results for mesenchymal translation from English to Maltese

endogenous kgf is an epithelial cell specific growth factor which is produced by mesenchymal cells and is naturally upregulated in response to epithelial tissue injury.
kgf endoġenu huwa fattur tat-tkabbir speċifiku taċ-ċelluli tal- epitilju li huwa magħmul minn ċelluli mesenkimali, u l-ħelsien tiegħu jiżdied b’mod naturali b’rispons għall-ħsara fit-tessut tal-epitilju.

these swellings are the result of local proliferation of mesenchymal tissue maturing to new bone and are consistent with the pharmacologic activity of rhbmp-2
dawn in-nefħiet huma riżultat ta’ proliferazzjoni tat-tessuti mesenkimali li jkunu qed jimmaturaw f’għadam ġdid u huma konsistenti mal-attività farmakoloġika ta’ rhbmp-2.

dibotermin alfa binds to receptors on the surface of mesenchymal cells and causes cells to differentiate into cartilage- and bone-forming cells.
dibotermin alfa jeħel mar-riċetturi fuq il-wiċċ ta’ ċelluli mesenchymal u jikkawża liċ- ċelluli biex li jinbidlu f’ċelluli li jiffurmaw il-kartilaġni u l-għadam.

eptotermin alfa, the active substance, initiates bone formation through the induction of cellular differentiation in mesenchymal cells, which are recruited to the implant site from bone marrow, periosteum and muscle.
eptotermin alfa, is- sustanza attiva, tibda l- formazzjoni ta 'l- għadam permezz ta' l- induzzjoni tad- differenzjazzjoni ċellulari fiċ- ċelluli mesenkimali, li huma reklutati għas- sit ta 'l- impjant mill- mudullum tal - għadam, il- perjosteum u l- muskolu.

additional efficacy data are available from a randomized, open-label, multicenter phase ii study [japiccti-121850] conducted in japanese patients with translocation-related sarcoma (trs), most common being myxoid round-cell liposarcoma (n=24), synovial sarcoma (n=18), mesenchymal chondrosarcoma (n=6), and extraskeletal ewing sarcoma/pnet, alveolar soft part sarcoma, alveolar rhabdomyosarcoma and clear cell sarcoma (n=5 each).
dejta addizzjonali dwar l-effikaċja hija disponibbli minn studju tal-fażi ii open-label, li fih il- parteċipanti ntgħażlu b’mod każwali u li sar f’’aktar minn ċentru wieħed, [japiccti-121850] li twettaq f’pazjenti Ġappuniżi b’sarkoma relatata mat-traslokazzjoni (translocation-related sarcoma - trs), bl-aktar komuni tkun liposarkoma myxoid taċ-ċelluli tondi (myxoid round-cell liposarcoma) (n=24), sarkoma sinovjali (n=18), kondrosarkoma mesenkimali (mesenchymal chondrosarcoma)(n=6), u sarkoma extraskeletali ewing/pnet, sarkoma tal-parti ratba alveolari (alveolar soft part sarcoma), rabdomijosarkoma alveolari u sarkoma taċ-ċelluli ċari (clear cell sarcoma ) (n=5 kull waħda).